JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (8): 69-71.doi: 10.6040/j.issn.1671-7554.0.2016.644

Previous Articles     Next Articles

Use of Cervista HPV HR A9 group virus to identify patients with negative cytological but positive high-risk HPV

WANG Yafen, YANG Yongxia, LIU Ya, MA Demei, ZHU Lin   

  1. Department of Gynaecology, The Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Received:2016-06-01 Online:2016-08-10 Published:2016-08-10

PDF (PC)

642

Abstract: Objective To analyze the cervical biopsy results in patients with negative cytological but positive high-risk HR-HPV test results, in order to explore the application of Cervista HPV HR A9 group virus in the identifying of such patients. Methods A total of 1,376 women who took physical examinations in our hospital during Jan. 2011 and Jan. 2016 received Cervista HR HPV test plus ThinPrep cytology(TCT). They were then divided into 3 groups according to the results of Cervista HR HPV test: A5/6, A7, and A9 groups. Those who had negative cytological but positive high-risk HPV test results underwent colposcopy or colposcopic biopsy if necessary. The correlation between A9 group virus infection and cervical high-grade intraepithelial neoplasia was analyzed. Results The positive rate in the A5/6, A7 and A9 group was respectively 28.41%, 21.51% and 28.41%. The incidence of CINII+ was 1.28%, 3.38% and 15.82%, respectively. The incidence of CINII+ in A9 group was obviously higher than that of the other two groups, and the difference was statistically significant(P<0.001, P<0.001). The risk of CINII+ in A9 group was 12.37 times of that in A5/A6 group and 4.68 times of that in A7 group. Conclusion Cervista HPV HR A9 group virus can be used to identify patients with negative cytological but positive high-risk HPV.

Key words: Human papilloma virus, Cervical cytological test, Cervical intraepithelial neoplasia, Cervical cancer

CLC Number: 

  • R574
[1] Castle PE, de Sanjosé S, Qiao YL, et al. Introduction of human papillomavirus DNA screening in the world: 15 years of experience[J]. Vaccine, 2012, 30 Suppl 5: F117-F122. doi: 10.1016/j.vaccine.2012.05.071.
[2] Zappacosta R, Caraceni D, Ciccocioppo L, et al. Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme[J]. Gynecol Oncol, 2013, 128(3): 427-432.
[3] Sabatino SA, White MC, Thompson TD, et al. Cancer screening test use-United States, 2013[J]. MMWR Morb Mortal Wkly Rep, 2015, 64(17): 464-468.
[4] Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women[J]. Br J Cancer, 2001, 84(12): 1616-1623.
[5] Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections[J]. J Natl Cancer Inst, 2008, 100(7): 513-517.
[6] Stoler MH, Castle PE, Solomon D, et al. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays[J]. Am J Clin Pathol, 2007, 127(3): 335-337.
[7] Cervical cancer screening and prevention. Practice Bulletin No.157. American College of Obstetricians and Gynecologists[J]. Obstet Gynecol, 2016, 127(1): e1-e20.
[8] Day SP, Hudson A, Mast A, et al. Analytical performance of the investigational use only Cervista HPV HR test as determined by a multi-center study[J]. J Clin Virol, 2009, 45 Suppl 1: S63-S72. doi: 10.1016/S1386-6532(09)70010-1.
[9] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-386.
[10] Zhao J, Du H, Belinson JL, et al. Evaluation of the Cervista HPV A9 group in screening patients for cervical cancer[J]. J Med Screen, 2016, 23(1): 38-43.
[11] de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study[J]. Lancet Oncol, 2010, 11(11): 1048-1056.
[12] Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States[J]. J Natl Cancer Inst, 2009, 101(7): 475-487.
[13] Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the international agency for research on cancer HPV prevalence surveys: a pooled analysis[J]. Lancet, 2005, 366(9490): 991-998.
[14] 李琳, 李坤. 女性生殖道人乳头瘤病毒多重感染基因谱的研究[J]. 现代妇产科进展, 2013, 22(7): 578-580.
[15] 梁凌云, 杜辉, 王纯, 等. 深圳人群人乳头瘤病毒感染亚型分布与宫颈上皮内瘤变现况横断面调查[J]. 北京大学学报(医学版), 2013, 45(1): 114-118. LIANG Lingyun, DU Hui, WANG Chun, et al. Crosssectional survey of human papilloma virus subtype distribution and cervical intraepithelial neoplasia in Shenzhen[J]. Journal of Peking University(Health Sciences), 2013, 45(1): 114-118.
[16] Liu XX, Fan XL, Yu YP, et al. Human papillomavirus prevalence and type-distribution among women in Zhejiang Province, southeast China: a cross-sectional study[J]. BMC Infect Dis, 2014, 14(1): 708.
[17] Ye J, Cheng X, Chen X, et al. Prevalence and risk profile of cervical human papillomavirus infection in Zhejiang Province, southeast China: a population-based study[J]. Virol J, 2010, 7: 66.
[18] Jing L, Zhong X, Zhong Z, et al. Prevalence of human papillomavirus infection in Guangdong Province, China: a population-based survey of 78,355 women[J]. Sex Transm Dis, 2014, 41(12): 732-738.
[19] Zhao J, Zhang X, Ma J, et al. Clinical performance characteristics of the Cervista HPV HR test kit in cervical cancer screening in China[J]. J Low Genit Tract Dis, 2012, 16(4): 358-363.
[1] WANG Lei, CHANG Xiao, WANG Zimeng, LI Jiaojiao, CUI Shujun, YANG Fei, ZHU Yuexiang. Predictive value of intratumoral and peritumoral DCE-MRI imaging histology for progression-free survival in patients with cervical cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 45-54.
[2] SHI Jun, NIU Zijie, WANG Jun, MA Lijing, XI Chunhua, XIAO Yang. Clinical features and anesthetic concerns in pulmonary dissemination of juvenile-onset recurrent respiratory papillomatosis [J]. Journal of Shandong University (Health Sciences), 2024, 62(12): 82-89.
[3] REN Huixin, ZHENG Maojin, HAN Wencan, WANG Chaoqun, ZHOU Yun, PEI Dongsheng. Hydrogen peroxide enhances radiotherapy sensitivity of cervical cancer by regulating autophagy [J]. Journal of Shandong University (Health Sciences), 2023, 61(6): 22-28.
[4] LIU Meng, HOU Congzhe, MA Huanyu, ZHANG Zhen, ZHAO Xinrui, ZHANG Ping, ZHU Lin. Effects of β-estradiol on the proliferation of cervical cancer Hela cells [J]. Journal of Shandong University (Health Sciences), 2023, 61(2): 9-15.
[5] XIU Dejian, GAO Zhengwen, SONG Tingting, CUI Nan, CUI Jing, SUN Jianping. Genes associated with cervical cancer by integrated bioinformatics analysis [J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 99-109.
[6] CHEN Quancai, HAN Sai, LIU Lu, SUN Yu, YOU Xuewu, ZHANG Junhua, ZHANG Youzhong. Expressions and significance of CDC7 and MCM4 in 105 cases of cervical lesions [J]. Journal of Shandong University (Health Sciences), 2022, 60(1): 34-39.
[7] LIANG Tingting, YANG Yongxia, HOU Congzhe, HUANG Taisheng, WANG Huali, ZHU Lin. Correlation among PAX1 methylation, high-grade cervical intraepithelial lesions and HR-HPV classification [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 48-52.
[8] YANG Jiaxin, SHEN Keng, WANG Yao. Status and prospect of fertility preservation treatment for gynecologic malignancies [J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 1-7.
[9] ZHOU Huimei, YANG Jiaxin, CAO Dongyan, SHEN Keng, XIANG Yang, WU Ming, PAN Lingya, HUANG Huifang, LANG Jinghe. Fertility-sparing radical trachelectomy for young women with early stage cervical cancer: surgical and obstetrical outcomes [J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 18-22.
[10] CHEN Ying, ZHOU Xiaoqing, QI Mei, ZHANG Weifang, LIU Juan, ZHAO Weiming. Effects of PRPS2 knockdown on the biological property of cervical cancer cells [J]. Journal of Shandong University (Health Sciences), 2018, 56(2): 9-13.
[11] WANG Yong, JIANG Chen, ZHOU Shiying, YANG Xiaomei. Effect of IQ motif-containing GTPase activating protein 3 on the proliferation and migration of cervical cancer cells [J]. Journal of Shandong University (Health Sciences), 2018, 56(10): 103-109.
[12] LIU Jingkang, YANG Jianyong, MENG Lihua, JIANG Jie. The value of serum miR-17-92 cluster in early diagnosis of HPV-positive cervical cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 86-90.
[13] SUN Zeyu, CHEN Ying, LIN Jiaxiang, LIU Juan, ZHAO Weiming. Influence of inositol polyphosphate-4-phosphatase type II on the proliferation and apoptosis of cervical cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(11): 1-6.
[14] WANG Yao, CUI Guoying, WANG Fei, LI Changzhong. Expression and significance of human leucocyte antigen-E in cervical cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(9): 59-63.
[15] PENG Hui, HE Junmei, SU Xuelian. Expression of serum miR-375 and its clinical significance in the diagnosis and postoperative monitoring of cervical cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 68-71.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd